Lung Cancer

Expert faculty review and share their insights and perspectives on key findings in lung cancer presented at the 2020 ASCO Annual Meeting.

Share

Program Content

Activities

  • ASCO 2020: Key Lung Cancer Studies
    Key Studies in Lung Cancer: Independent Conference Coverage of the ASCO 2020 Scientific Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 25, 2020

    Expires: September 24, 2021

  • EP: Lung Cancer
    ExpressPoints: Key Studies in Lung Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 25, 2020

    Expires: September 24, 2021

Activities

DESTINY-Lung01
Phase II DESTINY-Lung01: Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 30, 2020

Expires: May 29, 2021

CheckMate 227: 3-Year Update
First-line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced NSCLC: 3-Year Update of CheckMate 227 Part 1
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

ADAURA: Adj Osimertinib
Phase III ADAURA: Adjuvant Osimertinib vs Placebo After Complete Resection in Patients With Stage IB-IIIA EGFR-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

KEYNOTE-604
KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

CASPIAN
CASPIAN: Phase III Study of First-line Durvalumab + Tremelimumab + EP vs Durvalumab + EP vs EP Alone in Extensive-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2020

Expires: May 31, 2021

CheckMate 9LA
CheckMate 9LA: Nivolumab and Ipilimumab Plus 2 Cycles of Platinum-Doublet Chemotherapy vs 4 Cycles Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2020

Expires: June 01, 2021

RESILIENT: Liposomal Irinotecan
RESILIENT Part 1: Phase II Study of Liposomal Irinotecan After Platinum Chemotherapy in Small-Cell Lung Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2020

Expires: June 02, 2021

Lurbinectedin Plus Irinotecan
Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

GEOMETRY: Capmatinib in METamp+ NSCLC
Phase II GEOMETRY mono-1: Capmatinib in Patients With NSCLC and High MET Amplification
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2020

Expires: June 03, 2021

CITYSCAPE: Tiragolumab
Phase II CITYSCAPE: Addition of Tiragolumab, an Anti-TIGIT Antibody, to First-line Atezolizumab in PD-L1–Selected Metastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Expires: June 04, 2021

SINDAS Interim Analysis
Phase III SINDAS: Interim Analysis of First-line EGFR TKI With vs Without SBRT in Patients With EGFR-Mutated Oligometastatic NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2020

Expires: June 04, 2021

ARROW: Pralsetinib in <i>RET</i>+ NSCLC
Phase I/II ARROW: Registrational Dataset of RET Inhibitor Pralsetinib (BLU-667) in Patients With Advanced RET Fusion–Positive NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2020

Expires: June 07, 2021

ADJUVANT-CTONG 1104
ADJUVANT-CTONG 1104: Final OS Analysis of Phase III Study of Adjuvant Gefitinib vs Chemotherapy in Chinese Patients With Resected EGFR-Mutated NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2020

Expires: June 08, 2021

Faculty

cover img faculity

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

cover img faculity

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.